Quantcast

Afinitor (everolimus) tablets reduced the risk of progression of neuroendocrine tumors

Novartis has announced results of a Phase III pivotal study showing Afinitor (everolimus) tablets reduced the risk of progression by 52% vs placebo in patients with advanced, progressive, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin.

Read more